Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA;Lusomedicamenta, S.A.;Laboratorio Medinfar-Produtos Farmacêuticos, S.A.
发明人:
申请号：
EP16734481.1
公开号：
EP3302454A1
申请日:
2016.05.25
申请国别(地区):
EP
年份:
2018
代理人:
摘要：
The present invention relates to methods of treating and managing Parkinson's disease and related disorders. The methods especially find use in managing motor symptoms, including gait problems, particularly during advanced stages when effectiveness of standard medications wear off or side effects become problematic, as seen in Parkinson's disease, other disorders treated with dopaminergic agents, and other conditions associated with motor problems, such as aging or stroke. The treatment also may include disease-modifying effects, neuroprotection of, or neurorescue effects on neuronal cells in patients with Parkinson's disease and other neurodegenerative disorders. In particular, the invention relates to method of administering pharmaceutical compositions comprising effective amounts of tapentadol or a pharmaceutically acceptable salt or derivative thereof or, in other embodiments, stavudine or nabumetone, or a derivative thereof, for treating symptoms associated with Parkinson's disease, either as individual active agents, in combination with each other, or in combination with agents known to treat Parkinson's disease, such as the dopaminergic agent levodopa. The invention also relates to methods of preparing pharmaceutical compositions comprising effective amounts of tapentadol, stavudine, or nabumetone, or a derivative thereof, or further in combination with a dopaminergic agent, or derivative thereof, as well as to methods of using the pharmaceutical compositions in treating Parkinson's disease, related disorders, other conditions treated with dopaminergic agents, and other conditions with gait problems, for example by oral administration of the compositions.La présente invention concerne des méthodes de traitement et de gestion de la maladie de Parkinson et de troubles associés. Les méthodes sont particulièrement utilisées dans la gestion des symptômes moteurs, y compris les problèmes de démarche, en particulier au cours des stades avancés lorsque l'efficacité d
